BLUE is currently trading above its 50-day and 200-day simple moving averages (SMA), indicating a bullish trend. However, the 50-day SMA is below the 200-day SMA, forming a death cross pattern, which is a bearish signal.
The 20-day exponential moving average (EMA) is also above the current price, acting as a resistance level. A break above the 20-day EMA could...
Crazy volume on this one relative to it's history and .58 supply test and rejection but stock is still hovering above .4 resistance which is promising for longs.
I'm in at .3 and holding for .7 Target, to trim some along the way.
Bio-Rad Laboratories, Inc. manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. The company operates through Life Science and Clinical Diagnostics segments. The Life Science segment develops, manufactures, and markets a range of reagents, apparatus, and laboratory...
*This is not financial advice, so trade at your own risks*
*My team digs deep and finds stocks that are expected to perform well based off multiple confluences*
*Experienced traders understand the uphill battle in timing the market, so instead my team focuses mainly on risk management
My team entered Mirum Pharmaceuticals $MIRM today at $25 per share. Our...
We are finishing 1 to 5 Elliot wave theory and expecting price to bounce around 450$ zone.
Entry: 450 (institutional candle zone)
Invalidation 422 (Below buy zone)
Target: 644 (top of daily accumulation zone)
$AMGN is one of my favorite bio tech stocks as it has solidified its place as a winner over the years. They had a bit of a slowdown and consolidation over the past few years as they didn't have as much involvement with COVID, but certainly didn't lose too much value.
Watch for a 4hr close above $241.50 to send us back to $260+ over next few weeks.
All,
Castle looks like it would bounce pretty huge here at $37 double support. However, not in a bad spot now to reverse. Just wait and see clerly taking a beating.
Pulling back towards a potential buying zone ( 257.80 - 255.85)
Below that area we have a trendline that could also offer support.
Will wait for either a rejection off the buying zone or a break of the triangle
*This is not financial advice, so trade at your own risks*
*My team digs deep and finds stocks that are expected to perform well based off multiple confluences*
*Experienced traders understand the uphill battle in timing the market, so instead my team focuses mainly on risk management*
Recap: My team entered $MIRM on 10/29/21 at $15.70 per share. Our first...
Targeting 41$ .. Falling along with MRNA as vaccines should have less effect on peoples lives going forward.
MRNA chart will be posted next and that one should move down further than a company like Pfizer. Pfizer has a future, Moderna really does not.
All,
Just look at larger timeframes and price targets + last two EPS. I'm going in with 5% stop loss here. No reason not to. Undervalued, float is mediocre nothing great, but absolutely worth a stab here.
Edesa Biotech Inc (NASDAQ: EDSA) is surging higher Monday after the company announced positive Phase 2 data of its monoclonal antibody in hospitalized COVID-19 patients. Critically ill patients demonstrated a 68.5% reduction in the risk of dying when treated with EB05 over standard of care.
An independent Data and Safety Monitoring Board concluded that "a...
Hey everyone,
I hope you are doing fantastic!
$BNGO has presented us with an amazing set-up inside a channel.
We are currently sitting at the bottom of it and we have 2 TP ($8 and $10)
An amazing Risk-Reward with SL just above the channel.
I wish you all happy trading!
I have been tackling LABD/LABU day in and day out. I have somehow made some profit week by week. I am trying to figure out which was the better trade as I think it has come to the tipping point. I believe LABD is the winner. I see bearish sentiment in the short term market and I see an inverse head and shoulders or a cup and handle formation. On LABU I confirmed...
$BNTX Leaps Calls 680 Mar 17th 2023 Returns +403%
The FDA approval of Pfizer’s COVID-19 vaccine is a ‘critical step forward in vaccine confidence’: Doctor
